• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?

作者信息

Vergote Ignace, Amant Frederic, Leunen Karin

出版信息

Gynecol Oncol. 2010 Oct;119(1):1-2. doi: 10.1016/j.ygyno.2010.08.011.

DOI:10.1016/j.ygyno.2010.08.011
PMID:20833283
Abstract
摘要

相似文献

1
Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?晚期卵巢癌的新辅助化疗：需要何种证据才能说服美国妇科肿瘤学家？
Gynecol Oncol. 2010 Oct;119(1):1-2. doi: 10.1016/j.ygyno.2010.08.011.
2
The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.新辅助化疗在晚期卵巢癌患者管理中的作用：妇科肿瘤学家学会成员的调查结果。
Gynecol Oncol. 2010 Oct;119(1):18-21. doi: 10.1016/j.ygyno.2010.06.021. Epub 2010 Jul 31.
3
Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.
J Clin Oncol. 2007 Aug 10;25(23):3552; author reply 3557-8. doi: 10.1200/JCO.2007.12.2960.
4
What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?治疗晚期上皮性卵巢癌的妇科肿瘤学家目前的手术目标、策略和技术能力是什么？
Gynecol Oncol. 2001 Sep;82(3):489-97. doi: 10.1006/gyno.2001.6312.
5
Is the easier way ever the better way?更容易的方法就永远是更好的方法吗？
J Clin Oncol. 2011 Nov 1;29(31):4073-5. doi: 10.1200/JCO.2011.35.9935. Epub 2011 Sep 19.
6
Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?卵巢癌的治疗及生存率是否会因提供化疗的专科不同而有所差异？
J Clin Oncol. 2007 Aug 10;25(23):3554; author reply 3557-8. doi: 10.1200/JCO.2007.12.4974.
7
Influence of the gynecologic oncologist on the survival of ovarian cancer patients.妇科肿瘤学家对卵巢癌患者生存率的影响。
Obstet Gynecol. 2007 Jun;109(6):1342-50. doi: 10.1097/01.AOG.0000265207.27755.28.
8
LTE-commenting on "Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer" (90: 163-9).LTE——评论《对初始不可切除的晚期卵巢癌患者先进行新辅助化疗，然后手术及辅助化疗》（90: 163 - 9）。
Gynecol Oncol. 2004 Mar;92(3):1017-8; author reply 1018-9. doi: 10.1016/j.ygyno.2003.11.050.
9
Oncologist preferences for health states associated with the treatment of advanced ovarian cancer.肿瘤学家对与晚期卵巢癌治疗相关的健康状态的偏好。
Appl Health Econ Health Policy. 2010;8(4):217-23. doi: 10.2165/11317510-000000000-00000.
10
Type of oncology specialist and treatment-related outcomes in ovarian cancer.
J Clin Oncol. 2007 Aug 10;25(23):3553; author reply 3557-8. doi: 10.1200/JCO.2007.12.3422.

引用本文的文献

1
Proteomic alterations in ovarian cancer-Predicting residual disease status using artificial intelligence and SHAP-based biomarker interpretation.卵巢癌中的蛋白质组学改变——利用人工智能和基于SHAP的生物标志物解释预测残留疾病状态
Front Med (Lausanne). 2025 Jul 23;12:1562558. doi: 10.3389/fmed.2025.1562558. eCollection 2025.
2
Clinical and translational advances in ovarian cancer therapy.卵巢癌治疗的临床和转化进展。
Nat Cancer. 2023 Sep;4(9):1239-1257. doi: 10.1038/s43018-023-00617-9. Epub 2023 Aug 31.
3
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues.
新辅助化疗治疗的卵巢癌组织中与残留病灶相关的蛋白质组学改变
Clin Proteomics. 2022 Oct 4;19(1):35. doi: 10.1186/s12014-022-09372-y.
4
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.妇科肿瘤患者在 COVID-19 大流行期间的抗癌治疗和临床试验考虑。
Gynecol Oncol. 2020 Jul;158(1):16-24. doi: 10.1016/j.ygyno.2020.04.694. Epub 2020 Apr 23.
5
Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?原发灶治疗方法是否影响高级别浆液性卵巢癌的首次复发模式？
Gynecol Oncol. 2019 Nov;155(2):192-200. doi: 10.1016/j.ygyno.2019.08.011. Epub 2019 Sep 12.
6
Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.卵巢癌的影像学与治疗：纳米颗粒的临床应用及未来展望。
Theranostics. 2018 Jul 30;8(16):4279-4294. doi: 10.7150/thno.26345. eCollection 2018.
7
Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.美国晚期卵巢癌新辅助化疗与初次肿瘤细胞减灭术疗效比较中的方法学挑战综述
Cancer Epidemiol. 2018 Aug;55:8-16. doi: 10.1016/j.canep.2018.05.003. Epub 2018 May 25.
8
Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.采用积极手术模式的晚期上皮性卵巢癌新辅助化疗与初次肿瘤细胞减灭术的经济学分析。
Int J Gynecol Cancer. 2018 Jul;28(6):1077-1084. doi: 10.1097/IGC.0000000000001271.
9
Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.热腹腔内化疗灌注作为卵巢癌和原发性腹膜癌多模式治疗的一个组成部分。
J Surg Oncol. 2017 Sep;116(3):320-328. doi: 10.1002/jso.24666. Epub 2017 Jun 19.
10
Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.新辅助化疗后腹水消退对 IIIc 至 IV 期高级别浆液性卵巢癌治疗结局的预测作用
J Ovarian Res. 2016 Dec 2;9(1):85. doi: 10.1186/s13048-016-0294-z.